凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2016年第三季度报告全文

公告日期 2016-10-26
股票简称:莱茵生物 股票代码:002166
                桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文




桂林莱茵生物科技股份有限公司

     2016 年第三季度报告




        2016 年 10 月




                                                                  1
                                    桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人秦本军、主管会计工作负责人周庆伟及会计机构负责人(会计主

管人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                      2
                                                              桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文




                             第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
√ 是 □ 否

                                                                                                      本报告期末比上年度
                                                                        上年度末
                                   本报告期末                                                               末增减

                                                             调整前                 调整后                  调整后

总资产(元)                        2,132,697,622.66       2,029,927,403.13        2,029,927,403.13                  5.06%

归属于上市公司股东的净资产
                                     817,369,639.85         795,938,195.35          795,938,195.35                   2.69%
(元)

                                                       本报告期比上年同期                             年初至报告期末比上
                                    本报告期                                   年初至报告期末
                                                              增减                                        年同期增减

营业收入(元)                       122,914,106.29                  -12.21%        326,645,577.11                   4.35%

归属于上市公司股东的净利润
                                      15,725,429.43                  -65.69%         42,749,502.31               -24.35%
(元)

归属于上市公司股东的扣除非经
                                      14,691,877.75                  -67.37%         39,693,668.06               -25.65%
常性损益的净利润(元)

经营活动产生的现金流量净额
                                         --                    --                    97,849,998.05               -29.54%
(元)

基本每股收益(元/股)                           0.04                 -60.00%                   0.10              -23.08%

稀释每股收益(元/股)                           0.04                 -60.00%                   0.10              -23.08%

加权平均净资产收益率                           1.94%                  -4.09%                 5.31%                   -5.21%



会计政策变更的原因及会计差错更正的情况
    2015 年 1-9 月,子公司 LAYN USA 累计采购客户商品 64,001,183.72 元后再销售给同一客户,业务中仅提供相关劳务服
务并取得劳务收入,公司按全额确认了营业收入,同时确认了营业成本。根据《企业会计准则第 14 号——收入》相关规定,
按照实质重于形式原则,公司调减了 2015 年 1-3 季度定期报告中合并报表的营业收入和营业成本 64,001,183.72 元。
    本次更正对公司 2015 年 1-3 季度的利润和股东权益无影响。
    公司审计机构瑞华会计师事务所就上述事项出具了《关于桂林莱茵生物科技股份有限公司 2015 年 1-3 季度定期报告会
计差错更正的专项说明》(瑞华专函字[2016]45020002 号)。
    详细内容请参阅 2016 年 3 月 16 日刊登于《证券时报》、《中国证券报》和巨潮资讯网(www.cninfo.com.cn)的《关于
前期会计差错更正及追溯调整的公告》(公告编号:2016-018)。


非经常性损益项目和金额
√ 适用 □ 不适用


                                                                                                                              3
                                                            桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


                                                                                                              单位:元

                         项目                               年初至报告期期末金额                    说明

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                          2,835,874.51
一标准定额或定量享受的政府补助除外)

计入当期损益的对非金融企业收取的资金占用费                                 576,998.32

除上述各项之外的其他营业外收入和支出                                       174,345.43

减:所得税影响额                                                           531,384.01

合计                                                                      3,055,834.25                 --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                              单位:股

                                                          报告期末表决权恢复的优先
报告期末普通股股东总数                           70,743                                                             0
                                                          股股东总数(如有)

                                             前 10 名股东持股情况

                                                                        持有有限售条            质押或冻结情况
            股东名称             股东性质    持股比例      持股数量
                                                                        件的股份数量        股份状态         数量

秦本军                          境内自然人      17.57%     76,840,512       57,630,384 质押                 25,780,000

姚新德                          境内自然人       7.86%     34,361,643       25,771,232 质押                 34,361,534

梁定志                          境内自然人       4.77%     20,874,447

中央汇金资产管理有限责任公司 国有法人            4.46%     19,491,600

易红石                          境内自然人       2.33%     10,200,000                    质押                2,576,500

蒋安明                          境内自然人       2.13%      9,304,728                    质押                9,304,700

财通证券资管-宁波银行-财通
证券资管莱茵 1 号集合资产管理 其他               1.71%      7,498,703
计划

杨晓涛                          境内自然人       1.12%      4,889,400        4,889,400 质押                  4,889,400

财通基金-兴业银行-富春 182
                                其他             0.83%      3,643,026
号资产管理计划

中国农业银行股份有限公司-国 其他                0.72%      3,145,625


                                                                                                                         4
                                                          桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


泰国证医药卫生行业指数分级证
券投资基金

                                        前 10 名无限售条件股东持股情况

                                                                                             股份种类
              股东名称                       持有无限售条件股份数量
                                                                                       股份种类          数量

梁定志                                                                   20,874,447 人民币普通股        20,874,447

中央汇金资产管理有限责任公司                                             19,491,600 人民币普通股        19,491,600

秦本军                                                                   19,210,128 人民币普通股        19,210,128

易红石                                                                   10,200,000 人民币普通股        10,200,000

蒋安明                                                                    9,304,728 人民币普通股         9,304,728

姚新德                                                                    8,590,411 人民币普通股         8,590,411

财通证券资管-宁波银行-财通
证券资管莱茵 1 号集合资产管理                                             7,498,703 人民币普通股         7,498,703
计划

财通基金-兴业银行-富春 182
                                                                          3,643,026 人民币普通股         3,643,026
号资产管理计划

中国农业银行股份有限公司-国
泰国证医药卫生行业指数分级证                                              3,145,625 人民币普通股         3,145,625
券投资基金

陈兴华                                                                    2,655,700 人民币普通股         2,655,700

                                1.公司股东秦本军与蒋安明为兄弟关系,属于一致行动人。2.财通证券资管—宁波银行
上述股东关联关系或一致行动的 —财通证券资管莱茵 1 号集合资产管理计划系公司第一期员工持股计划账户。3.姚新德
说明                            系公司董事,杨晓涛系全资子公司莱茵投资执行董事。其与秦本军、蒋安明不存在一致
                                行动关系。4.其他股东之间关系不详。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                     5
                                                            桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文




                                            第三节 重要事项

一、报告期主要会计报表项目、财务指标发生变动的情况及原因

√ 适用 □ 不适用


     1.资产负债表项目变动幅度在30%以上的情况:



           项目             期末余额          期初余额          同比增减(%)                    变动原因

货币资金                    92,782,638.12     195,797,923.76          -52.61% 主要系报告期支付上海子公司购楼款所致
                                                                                主要系报告期支付上海子公司购楼款以及
在建工程                   283,494,433.79      72,520,928.98          290.91%
                                                                                新工厂建设支出增加所致
长期待摊费用                  976,303.78          331,143.83          194.83% 主要系GMP净化装修工程增加所致
                                                                                系部分预付新工厂的设备及工程款开票转
其他非流动资产              40,480,598.25      58,865,672.50          -31.23%
                                                                                入在建工程所致
                                                                                主要系报告期发放上年计提的绩效工资及
应付职工薪酬                 1,431,264.83        4,651,311.20         -69.23%
                                                                                奖金所致
                                                                                主要系报告期缴纳上年应交所得税等税款
应交税费                     4,904,238.17      11,395,090.88          -56.96%
                                                                                所致
                                                                                系报告期支付上年计提的按季支付的银行
应付利息                      195,900.00         1,025,147.57         -80.89%
                                                                                利息所致

一年内到期的非流动负债        921,256.00       66,842,512.00          -98.62% 主要系归还到期的银行贷款所致

长期借款                   100,000,000.00      70,000,000.00           42.86% 系银行长期贷款增加所致

递延收益                    44,948,900.00      25,984,900.00           72.98% 系报告期收到技改补助资金增加所致


     2.利润表项目金额变动幅度在30%以上的情况:


                         年初到本本报告
           项目                               上年同期          同比增减(%)                变动原因说明
                              期末

                                                                                主要系报告期BT项目执行“营改增”政策
营业税金及附加              -7,041,107.40        5,370,315.86        -231.11%
                                                                                所致
                                                                                主要系报告期植物提取业务运杂
销售费用                    12,482,072.12        9,165,475.46          36.19%
                                                                                费、参展费等增加所致
                                                                                主要系上年同期公司完成非公开发行股
财务费用                     5,926,914.10        2,123,367.43         179.13% 票,募集资金用于归还银行贷款、补充流
                                                                                动资金,公司贷款规模降低所致
                                                                                主要系报告期计提存货跌价准备较上年同
资产减值损失                  627,796.35         2,933,087.09          78.60%
                                                                                期减少所致



                                                                                                                   6
                                                            桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


                                                                                主要系上年同期赞助桂林市历史文物建设
营业外支出                        29,000.00      1,801,558.78         -98.39%
                                                                                工程款所致
所得税费用                     3,942,987.22      7,306,091.26         -46.03% 系报告期利润总额减少所致
                                                                                系报告期人民币汇率变动引起外币报表折
其他综合收益                     546,009.52      1,821,598.85         -70.03%
                                                                                算差额变动所致


     3.流量表项目金额变动幅度在30%以上的情况:


                           年初到本本报告
          项目                                上年同期          同比增减(%)                变动原因说明
                                 期末

                                                                                主要系报告期BT项目收到回购款比上同
经营活动现金流量净额          97,849,998.05   138,866,804.17          -29.54%
                                                                                期减少所致
投资活动现金流量净额        -183,984,741.89   -100,801,756.64         -82.52% 主要系报告期支付上海子公司购楼款所致
筹资活动现金流量净额         -16,840,879.33    -10,339,731.46         -62.88% 主要系报告期分红、支付利息增加所致


二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用
    1.嘉吉公司甜菊糖订单执行情况
    2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司LAYN USA与嘉吉股份有限公
司营养健康事业部正式签订了一份关于甜菊糖最终产品的长期独家《外包加工及供应协议》。根据协议的相关约定,该协议
已经自动续约至2017年11月1日止。2016年1-9月,公司与美国嘉吉公司执行订单总计约885万美元。
    2.BT项目合同
    2011年8月30日,公司披露了《关于全资子公司桂林莱茵投资有限公司签订BT项目合同的公告》。莱茵投资与湖南省建
筑工程集团总公司、湖南省建工园林工程有限公司组成的联合体与桂林市临桂新区管理委员会、桂林市临桂新区城市建设投
资有限公司、桂林市大禹水利基础设施建设投资有限公司签订了《桂林市临桂新区防洪排涝及湖塘水系工程投资、建设与移
交合同书》,BT项目总投资估算约为人民币16.2亿元,建安总投资不低于人民币13.2亿元,其余3亿元为工程建设其他费用
(综合费用)。
    截至2016年9月30日,根据桂林莱茵投资有限公司初步估算,BT项目已累计完成工程产值约10亿元。目前,BT项目已
累计收到回购款5.32亿元。2016年1-9月,莱茵投资实现营业收入67,031,289.08元,净利润12,073,597.75元(未经审计)。
    3.非公开发行股票事项
    2016年9月14日,公司收到中国证监会出具的《中国证监会行政许可项目审查二次反馈意见通知书》(160463号),公
司会同相关中介机构对《二次反馈意见》提出的问题进行了认真核查和回复准备,为切实做好反馈意见回复工作,经与保荐
机构审慎协商,公司于2016年9月28日向中国证监会递交了延期回复的申请,申请将反馈意见回复期限延长至2016年11月8
日前回复。
    目前,公司董事会及相关中介机构正积极落实二次反馈的相关工作。
    4.关于在上海购置房产的事项
    为满足公司2015年度非公开发行股票募集资金用途之一“植物健康产品研发中心建设项目”以及未来终端业务发展的需
要,经公司2016年第1次临时股东大会审议通过,2016年2月24日,公司的全资子公司上海碧研生物技术有限公司与上海华虹
置业有限公司签订了《商品房预售合同》,合同约定以暂定价人民币155,043,420元(不包含房屋全装修价格)购买上海华虹
置业有限公司位于上海市浦东新区锦绣东路2777弄“华虹创新园三期建设项目”40号全幢室。公司已按合同约定的方式进行分
期付款,目前,房屋已经交付并进入装修设计阶段。




                                                                                                                     7
                                                             桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


             重要事项概述                            披露日期                       临时报告披露网站查询索引

                                                                              巨潮资讯网(www.cninfo.com.cn),《BT
BT 项目                              2016 年 10 月 13 日                      项目合同实施进展公告》(公告编号
                                                                              2016-081)。

                                                                              巨潮资讯网(www.cninfo.com.cn),《关
                                                                              于非公开发行股票申请文件二次反馈意
非公开发行股票                       2016 年 09 月 28 日
                                                                              见延期回复的公告》,公告编号
                                                                              2016-077)。

                                                                              巨潮资讯网(www.cninfo.com.cn),《关
上海购置房产事项                     2016 年 02 月 26 日                      于在上海购买房产的公告》,公告编号
                                                                              2016-014)。


三、公司、股东、实际控制人、收购人、董事、监事、高级管理人员或其他关联方在报告期
内履行完毕及截至报告期末尚未履行完毕的承诺事项

√ 适用 □ 不适用

            承诺事由               承诺方        承诺类型       承诺内容      承诺时间       承诺期限    履行情况

股改承诺

收购报告书或权益变动报告书中所
作承诺

资产重组时所作承诺

                                                             本人将不在
                                                             中国境内外
                                                             直接或间接
                                                             从事或参与
                                                             任何在商业
                                                             上对股份公
                                                             司构成竞争
                                                             的业务或活
                                                             动,或拥有与
                                                                                                        截至本报告
                                 秦本军、姚新                股份公司存
                                                同业竞争承                  2007 年 09 月               披露日,该承
首次公开发行或再融资时所作承诺 德、杨晓涛及                  在竞争关系                     长期
                                                诺                          13 日                       诺正在履行
                                 蒋安明                      的任何经济
                                                                                                        中。
                                                             实体、机构、
                                                             经济组织的
                                                             权益,或以其
                                                             他任何形式
                                                             取得该经济
                                                             实体、机构、
                                                             经济组织的
                                                             控制权,或在
                                                             该经济实体、


                                                                                                                       8
                            桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


                            机构、经济组
                            织中担任高
                            级管理人员
                            或核心技术
                            人员。

                            1、自莱茵生
                            物本次非公
                            开发行股票
                            的定价基准
                            日前六个月
                            至今,本人不
                            存在减持公
                            司股票的行
                            为。2、自本
                            承诺出具之
                            日起至莱茵
                            生物本次非
                            公开发行完
                            成后六个月
                            内,本人将不
                            减持莱茵生                      至公司本次   截至本报告
秦本军、蒋小 股票限售承     物股票(包括 2016 年 04 月 非公开发行        披露日,该承
三             诺           承诺期间因      26 日           完成后六个   诺正在履行
                            莱茵生物发                      月内         中。
                            生资本公积
                            转增股本、派
                            送股票红利、
                            配股、增发等
                            产生的股
                            票)。3、若本
                            人违反上述
                            承诺减持莱
                            茵生物股票,
                            减持股票所
                            得收益将全
                            部上缴莱茵
                            生物,并承担
                            由此引发的
                            法律责任。

本公司、控股                本公司及本
                                                                         截至本报告
股东秦本军                  公司关联方                      至公司本次
               不存在财务                   2016 年 04 月                披露日,该承
及其一致行                  未违反《证券                    非公开发行
               资助的承诺                   26 日                        诺正在履行
动人蒋安明、                发行与承销                      完成后
                                                                         中。
蒋小三、公司                管理办法》第

                                                                                        9
                                                         桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


                                 持股 5%以上              十六条等有
                                 股东姚新德               关法规的规
                                                          定,不存在直
                                                          接或间接对
                                                          认购莱茵生
                                                          物本次非公
                                                          开发行股票
                                                          的投资公司、
                                                          资管产品及
                                                          其委托人、合
                                                          伙企业及其
                                                          合伙人提供
                                                          财务资助或
                                                          者补偿的情
                                                          况。

股权激励承诺

其他对公司中小股东所作承诺

承诺是否按时履行                 是


四、对 2016 年度经营业绩的预计

2016 年度预计的经营业绩情况:
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2016 年度归属于上市公司股东的净利润变动幅度                         -30%        至                         0

2016 年度归属于上市公司股东的净利润变动区间(万元)              5,270.94       至                   7,529.92

2015 年度归属于上市公司股东的净利润(万元)                                                          7,529.92

                                                      得益于公司前期战略调整规划的深入落实,公司预计 2016 年
                                                      度植物提取业务销售收入较上年度将取得增长,将对公司 2016
                                                      年度业绩产生较大积极影响。但由于 BT 项目上年度部分单位
业绩变动的原因说明
                                                      工程完成验收实现了较多利润,本年度 BT 项目的业绩贡献与
                                                      上年度相比将大幅降低,因此预计将导致公司 2016 年度整体
                                                      业绩较上年度下滑。


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。




                                                                                                            10
                                                        桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用
公司报告期内未发生接待调研、沟通、采访等活动。




                                                                                                          11
                                                       桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文




                                         第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                           2016 年 09 月 30 日
                                                                                                     单位:元

                 项目                           期末余额                             期初余额

流动资产:

    货币资金                                                 92,782,638.12                   195,797,923.76

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据

    应收账款                                                 44,632,039.94                      51,431,974.01

    预付款项                                                 13,314,896.03                      11,060,209.96

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                                 10,571,602.30                       9,994,603.98

    应收股利                                                     3,816,791.10

    其他应收款                                               22,185,940.04                      23,874,531.26

    买入返售金融资产

    存货                                                   1,080,030,760.59                1,057,638,660.39

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                             10,759,514.03                      10,519,497.77

流动资产合计                                               1,278,094,182.15                1,360,317,401.13

非流动资产:

    发放贷款及垫款



                                                                                                           12
                                     桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


    可供出售金融资产                      73,569,900.50                     73,569,900.50

    持有至到期投资

    长期应收款                            15,960,000.00                     15,960,000.00

    长期股权投资

    投资性房地产                         255,653,369.41                    258,930,935.95

    固定资产                             123,144,640.56                    131,085,820.37

    在建工程                             283,494,433.79                     72,520,928.98

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                              54,740,944.99                     51,458,547.96

    开发支出

    商誉

    长期待摊费用                             976,303.78                       331,143.83

    递延所得税资产                         6,583,249.23                      6,887,051.91

    其他非流动资产                        40,480,598.25                     58,865,672.50

非流动资产合计                           854,603,440.51                    669,610,002.00

资产总计                               2,132,697,622.66                  2,029,927,403.13

流动负债:

    短期借款                             290,000,000.00                    235,000,000.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据

    应付账款                             165,861,728.02                    213,770,705.63

    预收款项                             502,608,537.81                    396,487,568.80

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                           1,431,264.83                      4,651,311.20

    应交税费                               4,904,238.17                     11,395,090.88




                                                                                       13
                             桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


    应付利息                         195,900.00                      1,025,147.57

    应付股利

    其他应付款                    12,935,106.12                     15,482,020.40

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债           921,256.00                     66,842,512.00

    其他流动负债                   9,845,275.06                     11,941,333.78

流动负债合计                     988,703,306.01                    956,595,690.26

非流动负债:

    长期借款                     100,000,000.00                     70,000,000.00

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                   179,909,426.92                    179,909,426.92

    预计负债

    递延收益                      44,948,900.00                     25,984,900.00

    递延所得税负债                 1,585,740.34                      1,499,190.60

    其他非流动负债

非流动负债合计                   326,444,067.26                    277,393,517.52

负债合计                       1,315,147,373.27                  1,233,989,207.78

所有者权益:

    股本                         437,281,362.00                    437,281,362.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                     261,669,420.58                    261,669,420.58

    减:库存股

    其他综合收益                   2,780,798.76                      2,234,789.24

    专项储备



                                                                               14
                                                         桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


    盈余公积                                                     12,184,826.12                    12,184,826.12

    一般风险准备

    未分配利润                                                  103,453,232.39                    82,567,797.41

归属于母公司所有者权益合计                                      817,369,639.85                 795,938,195.35

    少数股东权益                                                    180,609.54

所有者权益合计                                                  817,550,249.39                 795,938,195.35

负债和所有者权益总计                                           2,132,697,622.66              2,029,927,403.13


法定代表人:秦本军                     主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏


2、母公司资产负债表

                                                                                                       单位:元

                   项目                             期末余额                           期初余额

流动资产:

    货币资金                                                     84,930,949.83                 193,484,716.82

    以公允价值计量且其变动计入当期损
益的金融资产

    衍生金融资产

    应收票据

    应收账款                                                     93,145,646.74                    59,362,847.94

    预付款项                                                     11,009,085.12                     9,868,748.82

    应收利息

    应收股利                                                       3,816,791.10

    其他应收款                                                  224,038,629.78                 147,626,660.28

    存货                                                        128,601,342.72                 199,976,794.14

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                                   3,654,022.27                   10,263,808.96

流动资产合计                                                    549,196,467.56                 620,583,576.96

非流动资产:

    可供出售金融资产                                             73,569,900.50                    73,569,900.50

    持有至到期投资

    长期应收款

    长期股权投资                                                 69,798,792.27                    39,298,792.27

    投资性房地产                                                255,653,369.41                 258,930,935.95


                                                                                                             15
                                       桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


    固定资产                               118,912,905.63                    127,363,935.89

    在建工程                               154,249,475.67                     72,149,630.98

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                                53,597,238.79                     50,630,193.06

    开发支出

    商誉

    长期待摊费用

    递延所得税资产                            6,580,898.37                     6,884,872.46

    其他非流动资产                          39,226,198.25                     58,865,672.50

非流动资产合计                             771,588,778.89                    687,693,933.61

资产总计                                  1,320,785,246.45                 1,308,277,510.57

流动负债:

    短期借款                               260,000,000.00                    235,000,000.00

    以公允价值计量且其变动计入当期损
益的金融负债

    衍生金融负债

    应付票据

    应付账款                                34,770,707.72                     21,922,296.88

    预收款项                                12,880,459.90                      7,502,639.20

    应付职工薪酬                              1,041,749.16                     3,499,425.21

    应交税费                                  3,454,590.01                      338,646.17

    应付利息                                                                    991,897.57

    应付股利

    其他应付款                              29,767,150.87                     32,289,234.71

    划分为持有待售的负债

    一年内到期的非流动负债                     921,256.00                     66,842,512.00

    其他流动负债

流动负债合计                               342,835,913.66                    368,386,651.74

非流动负债:

    长期借款

    应付债券




                                                                                         16
                                       桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                                 179,909,426.92                  179,909,426.92

    预计负债

    递延收益                                    44,948,900.00                   25,984,900.00

    递延所得税负债

    其他非流动负债

非流动负债合计                                 224,858,326.92                  205,894,326.92

负债合计                                       567,694,240.58                  574,280,978.66

所有者权益:

    股本                                       437,281,362.00                  437,281,362.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                                   261,669,420.59                  261,669,420.59

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                    12,184,826.12                   12,184,826.12

    未分配利润                                  41,955,397.16                   22,860,923.20

所有者权益合计                                 753,091,005.87                  733,996,531.91

负债和所有者权益总计                         1,320,785,246.45              1,308,277,510.57


3、合并本报告期利润表

                                                                                     单位:元

                 项目         本期发生额                          上期发生额

一、营业总收入                             122,914,106.29                      140,005,579.43

    其中:营业收入                         122,914,106.29                      140,005,579.43

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                             109,985,950.20                       87,873,587.50



                                                                                           17
                                      桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


    其中:营业成本                     93,863,554.02                         68,726,404.45

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             营业税金及附加               374,142.18                          4,512,075.07

             销售费用                   4,046,221.98                          3,279,389.63

             管理费用                  10,522,794.53                         11,141,056.34

             财务费用                   1,188,025.10                           214,662.01

             资产减值损失                  -8,787.61

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                        3,816,791.10
列)

             其中:对联营企业和合营
企业的投资收益

         汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)     16,744,947.19                         52,131,991.93

    加:营业外收入                      1,314,709.78                           722,886.00

         其中:非流动资产处置利得

    减:营业外支出                          1,000.00                           150,000.00

         其中:非流动资产处置损失

四、利润总额(亏损总额以“-”号填
                                       18,058,656.97                         52,704,877.93
列)

    减:所得税费用                      2,342,618.00                          6,884,371.47

五、净利润(净亏损以“-”号填列)     15,716,038.97                         45,820,506.46

    归属于母公司所有者的净利润         15,725,429.43                         45,829,616.67

    少数股东损益                           -9,390.46                             -9,110.21

六、其他综合收益的税后净额                394,228.06                           996,049.14

  归属母公司所有者的其他综合收益
                                          394,228.06                           996,049.14
的税后净额

    (一)以后不能重分类进损益的


                                                                                        18
                                                        桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
                                                             394,228.06                           996,049.14
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额                          394,228.06                           996,049.14

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                           16,110,267.03                        46,816,555.60

    归属于母公司所有者的综合收益
                                                           16,119,657.49                        46,825,665.81
总额

    归属于少数股东的综合收益总额                               -9,390.46                             -9,110.21

八、每股收益:

    (一)基本每股收益                                              0.04                                 0.10

    (二)稀释每股收益                                              0.04                                 0.10

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元,上期被合并方实现的净利润为:元。


法定代表人:秦本军                    主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏


4、母公司本报告期利润表

                                                                                                     单位:元

                 项目                         本期发生额                           上期发生额

一、营业收入                                               89,517,393.57                        79,792,022.80

    减:营业成本                                           70,103,336.97                        63,242,907.38



                                                                                                            19
                                      桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


         营业税金及附加                   289,492.88                           577,240.18

         销售费用                       2,215,602.38                          2,003,711.67

         管理费用                       8,040,709.53                          9,114,547.18

         财务费用                         647,693.11                         -3,966,139.00

         资产减值损失                      32,720.46

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                        3,816,791.10                         40,000,000.00
列)

         其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)     12,004,629.34                         48,819,755.39

    加:营业外收入                      1,314,709.78                           722,886.00

         其中:非流动资产处置利得

    减:营业外支出

         其中:非流动资产处置损失

三、利润总额(亏损总额以“-”号填
                                       13,319,339.12                         49,542,641.39
列)

    减:所得税费用                      1,422,705.60

四、净利润(净亏损以“-”号填列)     11,896,633.52                         49,542,641.39

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益



                                                                                        20
                                               桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


           4.现金流量套期损益的有
效部分

           5.外币财务报表折算差额

           6.其他

六、综合收益总额                                    11,896,633.52                       49,542,641.39

七、每股收益:

    (一)基本每股收益                                       0.03                                0.11

    (二)稀释每股收益                                       0.03                                0.11


5、合并年初到报告期末利润表

                                                                                             单位:元

                 项目                 本期发生额                          上期发生额

一、营业总收入                                     326,645,577.11                      313,042,042.57

    其中:营业收入                                 326,645,577.11                      313,042,042.57

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                                     287,164,155.59                      253,774,118.73

    其中:营业成本                                 245,119,060.17                      206,337,341.03

           利息支出

           手续费及佣金支出

           退保金

           赔付支出净额

           提取保险合同准备金净额

           保单红利支出

           分保费用

           营业税金及附加                           -7,041,107.40                        5,370,315.86

           销售费用                                 12,482,072.12                        9,165,475.46

           管理费用                                 30,049,420.25                       27,844,531.86

           财务费用                                  5,926,914.10                        2,123,367.43

           资产减值损失                               627,796.35                         2,933,087.09

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                     4,191,457.61                        3,575,899.18
列)


                                                                                                   21
                                      桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


         其中:对联营企业和合营企
业的投资收益

         汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)     43,672,879.13                         62,843,823.02

    加:营业外收入                      3,039,219.94                          2,755,023.16

         其中:非流动资产处置利得

    减:营业外支出                         29,000.00                          1,801,558.78

         其中:非流动资产处置损失                                               80,881.82

四、利润总额(亏损总额以“-”号填
                                       46,683,099.07                         63,797,287.40
列)

    减:所得税费用                      3,942,987.22                          7,306,091.26

五、净利润(净亏损以“-”号填列)     42,740,111.85                         56,491,196.14

    归属于母公司所有者的净利润         42,749,502.31                         56,509,284.11

    少数股东损益                           -9,390.46                            -18,087.97

六、其他综合收益的税后净额                546,009.52                          1,821,598.85

  归属母公司所有者的其他综合收益
                                          546,009.52                          1,821,598.85
的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
                                          546,009.52                          1,821,598.85
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额       546,009.52                          1,821,598.85



                                                                                        22
                                                        桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                            43,286,121.37                        58,312,794.99

    归属于母公司所有者的综合收益
                                                            43,295,511.83                        58,330,882.96
总额

    归属于少数股东的综合收益总额                                -9,390.46                           -18,087.97

八、每股收益:

    (一)基本每股收益                                               0.10                                 0.13

    (二)稀释每股收益                                               0.10                                 0.13

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元,上期被合并方实现的净利润为:元。


6、母公司年初到报告期末利润表

                                                                                                      单位:元

                 项目                         本期发生额                           上期发生额

一、营业收入                                               272,332,121.53                       209,264,547.83

    减:营业成本                                           201,507,453.38                       168,516,336.08

           营业税金及附加                                     718,096.46                          1,106,001.88

           销售费用                                          6,207,673.21                         5,497,317.41

           管理费用                                         23,628,808.61                        22,979,699.13

           财务费用                                          4,017,966.66                        -2,307,217.60

           资产减值损失                                       740,288.60                          2,863,791.58

    加:公允价值变动收益(损失以
“-”号填列)

           投资收益(损失以“-”号填
                                                             4,191,457.61                        43,575,899.18
列)

           其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)                          39,703,292.22                        54,184,518.53

    加:营业外收入                                           2,993,561.77                         2,755,023.16

           其中:非流动资产处置利得

    减:营业外支出                                              28,000.00                            91,558.78

           其中:非流动资产处置损失                                                                  80,881.82

三、利润总额(亏损总额以“-”号填
                                                            42,668,853.99                        56,847,982.91
列)




                                                                                                            23
                                               桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


     减:所得税费用                                  1,710,312.70                         133,107.30

四、净利润(净亏损以“-”号填列)                  40,958,541.29                       56,714,875.61

五、其他综合收益的税后净额

     (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

     (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                                    40,958,541.29                       56,714,875.61

七、每股收益:

     (一)基本每股收益                                      0.09                                0.13

     (二)稀释每股收益                                      0.09                                0.13


7、合并年初到报告期末现金流量表

                                                                                             单位:元

                 项目                 本期发生额                          上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                  386,725,521.66                      498,915,257.74

     客户存款和同业存放款项净增加


     向中央银行借款净增加额




                                                                                                   24
                                    桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


     向其他金融机构拆入资金净增加


     收到原保险合同保费取得的现金

     收到再保险业务现金净额

     保户储金及投资款净增加额

     处置以公允价值计量且其变动计
入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还                  15,644,876.63                          6,849,692.00

     收到其他与经营活动有关的现金     6,219,627.73                          5,672,160.08

经营活动现金流入小计                408,590,026.02                        511,437,109.82

     购买商品、接受劳务支付的现金   238,316,230.75                        301,905,399.05

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增加


     支付原保险合同赔付款项的现金

     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的现
                                     32,611,959.52                         28,291,713.47


     支付的各项税费                  15,546,131.83                         14,968,605.87

     支付其他与经营活动有关的现金    24,265,705.87                         27,404,587.26

经营活动现金流出小计                310,740,027.97                        372,570,305.65

经营活动产生的现金流量净额           97,849,998.05                        138,866,804.17

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金             374,666.51                           387,586.05

     处置固定资产、无形资产和其他
                                      5,000,000.00                          1,000,000.00
长期资产收回的现金净额

     处置子公司及其他营业单位收到
的现金净额

     收到其他与投资活动有关的现金    18,964,000.00                          6,613,000.00

投资活动现金流入小计                 24,338,666.51                          8,000,586.05

     购建固定资产、无形资产和其他   206,107,408.40                         65,539,534.69


                                                                                      25
                                             桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


长期资产支付的现金

    投资支付的现金                                                                    40,262,808.00

    质押贷款净增加额

    取得子公司及其他营业单位支付
的现金净额

    支付其他与投资活动有关的现金                   2,216,000.00                        3,000,000.00

投资活动现金流出小计                             208,323,408.40                      108,802,342.69

投资活动产生的现金流量净额                   -183,984,741.89                      -100,801,756.64

三、筹资活动产生的现金流量:

    吸收投资收到的现金                              190,000.00                       486,199,491.73

    其中:子公司吸收少数股东投资
收到的现金

    取得借款收到的现金                           260,000,000.00                      480,000,000.00

    发行债券收到的现金

    收到其他与筹资活动有关的现金                   7,000,000.00

筹资活动现金流入小计                             267,190,000.00                      966,199,491.73

    偿还债务支付的现金                           240,000,000.00                      842,967,952.61

    分配股利、利润或偿付利息支付
                                                  36,030,879.33                       15,571,270.58
的现金

    其中:子公司支付给少数股东的
股利、利润

    支付其他与筹资活动有关的现金                   8,000,000.00                      118,000,000.00

筹资活动现金流出小计                             284,030,879.33                      976,539,223.19

筹资活动产生的现金流量净额                       -16,840,879.33                      -10,339,731.46

四、汇率变动对现金及现金等价物的
                                                     -39,726.37                         -180,422.07
影响

五、现金及现金等价物净增加额                 -103,015,349.54                          27,544,894.00

    加:期初现金及现金等价物余额                 195,797,987.66                       70,246,510.73

六、期末现金及现金等价物余额                      92,782,638.12                       97,791,404.73


8、母公司年初到报告期末现金流量表

                                                                                           单位:元

              项目                  本期发生额                          上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                 252,949,382.50                      244,497,348.21



                                                                                                 26
                                    桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


     收到的税费返还                  15,644,876.63                          6,849,692.00

     收到其他与经营活动有关的现金     6,140,333.14                          4,681,962.38

经营活动现金流入小计                274,734,592.27                        256,029,002.59

     购买商品、接受劳务支付的现金   113,890,855.67                        122,071,108.06

     支付给职工以及为职工支付的现
                                     24,448,716.00                         21,293,630.73


     支付的各项税费                   1,944,437.79                          5,127,570.93

     支付其他与经营活动有关的现金    16,066,516.56                         16,093,112.95

经营活动现金流出小计                156,350,526.02                        164,585,422.67

经营活动产生的现金流量净额          118,384,066.25                         91,443,579.92

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金             374,666.51                           387,586.05

     处置固定资产、无形资产和其他
                                      5,000,000.00                          1,000,000.00
长期资产收回的现金净额

     处置子公司及其他营业单位收到
的现金净额

     收到其他与投资活动有关的现金    18,964,000.00                          6,613,000.00

投资活动现金流入小计                 24,338,666.51                          8,000,586.05

     购建固定资产、无形资产和其他
                                     67,486,021.51                         64,908,611.69
长期资产支付的现金

     投资支付的现金                  30,500,000.00                         51,262,808.00

     取得子公司及其他营业单位支付
的现金净额

     支付其他与投资活动有关的现金     2,216,000.00                          3,000,000.00

投资活动现金流出小计                100,202,021.51                        119,171,419.69

投资活动产生的现金流量净额           -75,863,355.00                      -111,170,833.64

三、筹资活动产生的现金流量:

     吸收投资收到的现金                                                   486,199,491.73

     取得借款收到的现金             200,000,000.00                        330,000,000.00

     发行债券收到的现金

     收到其他与筹资活动有关的现金    86,000,000.00                         27,400,000.00

筹资活动现金流入小计                286,000,000.00                        843,599,491.73

     偿还债务支付的现金             240,000,000.00                        472,967,952.61

     分配股利、利润或偿付利息支付
                                     32,132,012.67                          5,806,209.47
的现金


                                                                                      27
                                    桂林莱茵生物科技股份有限公司 2016 年第三季度报告全文


     支付其他与筹资活动有关的现金   164,990,000.00                        336,196,688.46

筹资活动现金流出小计                437,122,012.67                        814,970,850.54

筹资活动产生的现金流量净额          -151,122,012.67                        28,628,641.19

四、汇率变动对现金及现金等价物的
                                         47,534.43                           -249,433.31
影响

五、现金及现金等价物净增加额        -108,553,766.99                         8,651,954.16

     加:期初现金及现金等价物余额   193,484,716.82                         67,274,233.48

六、期末现金及现金等价物余额         84,930,949.83                         75,926,187.64


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。




                                                      桂林莱茵生物科技股份有限公司


                                                      法定代表人:

                                                                         秦本军

                                                                 2016 年 10 月 24 日




                                                                                      28
数据加载中...
prevnext
手机查看股票